A006620 logo

DongKoo Bio & Pharma Co., Ltd. Stock Price

KOSDAQ:A006620 Community·₩138.5b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

A006620 Share Price Performance

₩0
-5030.00 (-100.00%)
₩0
-5030.00 (-100.00%)
Price ₩0

A006620 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Solid track record with low risk.

3 Risks
2 Rewards

DongKoo Bio & Pharma Co., Ltd. Key Details

₩242.7b

Revenue

₩98.3b

Cost of Revenue

₩144.3b

Gross Profit

₩94.1b

Other Expenses

₩50.3b

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
1.86k
59.48%
20.71%
84.1%
View Full Analysis

About A006620

Founded
1970
Employees
393
CEO
Cho Yong-Jun
WebsiteView website
www.dongkoo.com

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antipyretic anti-inflammatory analgesics, and for the treatment of the respiratory, digestive, genitourinary, and circulatory systems; and quasi-drugs. It offers cosmetic products under the CELL BLOOM brand; MediBloom MD Lotion/Cream for wound treatment; and medical devices for skin therapy, aesthetic, scalp care, and skin diagnosis. In addition, the company develops DKB15003 for dyslipidemia; DKB17001 for BPH/OAB; DKB17002 for Lumbago; DKB19001 for hypertension/dyslipidemia; DKB19002, DKB20001, DKB20002, DKB20004, DKB1903, DKB1903C, and DKB2001 for diabetes; DKB19003 for allergic rhinitis; DKB20003 for venous lymphatic insufficiency; NCP112 for atopic dermatitis; DKB1904 for allergy/dermatitis; DKB1801 for acne; and DKB1902 and DKB2014 for psoriasis. Further, it engages in new technology, financial, pharmaceutical marketing, and agency businesses. The company was formerly known as DongKoo Pharm Co., Ltd. and changed its name to DongKoo Bio & Pharma Co., Ltd. in January 2014. The company was founded in 1970 and is headquartered in Seoul, South Korea.

Recent A006620 News & Updates

DongKoo Bio & Pharma's (KOSDAQ:006620) Earnings Are Built On Soft Foundations

Apr 01
DongKoo Bio & Pharma's (KOSDAQ:006620) Earnings Are Built On Soft Foundations

Recent updates

No updates